May 2, 2023 07:06 AM EDTUpdated 10:44 AM
Deals
Bioregnum

J&J goes block­buster hunt­ing (again) with $245M cash up­front for next-gen CAR-T

J&J is work­ing on cre­at­ing its next Leg­end. On­ly this time, it’s mov­ing right in­to the dri­ver’s seat in­stead of tak­ing the co-pi­lot role. …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times